Modulation of Leukocyte Infiltration and Phenotype in Microporous Tissue Engineering Scaffolds via Vector Induced Il-10 Expression by Gower, R. Michael et al.
University of South Carolina
Scholar Commons
Faculty Publications Chemical Engineering, Department of
Spring 2-2014
Modulation of Leukocyte Infiltration and
Phenotype in Microporous Tissue Engineering
Scaffolds via Vector Induced Il-10 Expression
R. Michael Gower





See next page for additional authors
Follow this and additional works at: https://scholarcommons.sc.edu/eche_facpub
Part of the Biomedical Engineering and Bioengineering Commons, and the Chemical
Engineering Commons
This Article is brought to you by the Chemical Engineering, Department of at Scholar Commons. It has been accepted for inclusion in Faculty
Publications by an authorized administrator of Scholar Commons. For more information, please contact dillarda@mailbox.sc.edu.
Publication Info
Published in Biomaterials, Volume 35, Issue 6, Spring 2014, pages 2024-2031.
© Biomaterials, 2014, Elsevier.
Gower, R., Boehler, R., Azarin, S., Ricci, C., Leonard, J., & Shea, L. (2014). Modulation of leukocyte infiltration and phenotype in
microporous tissue engineering scaffolds via vector induced IL-10 expression. Biomaterials, 35(6), 2024-2031.
doi: 10.1016/j.biomaterials.2013.11.036
Author(s)
R. Michael Gower, Ryan M. Boehler, Samira M. Azarin, Christine F. Ricci, Joshua N. Leonard, and Lonnie D.
Shea
This article is available at Scholar Commons: https://scholarcommons.sc.edu/eche_facpub/1096
University of South Carolina
Scholar Commons
Accounting Faculty Publications School of Accounting, The
Spring 2-2014
Modulation of leukocyte infiltration and
phenotype in microporous tissue engineering
scaffolds via vector induced IL-10 expression
Michael Gower
Follow this and additional works at: https://scholarcommons.sc.edu/acc_facpub
Part of the Biomedical Engineering and Bioengineering Commons, and the Chemical
Engineering Commons
Modulation of leukocyte infiltration and phenotype in microporous
tissue engineering scaffolds via vector induced IL-10 expression
R. Michael Gower a, Ryan M. Boehler a, Samira M. Azarin a, Christine F. Ricci a,
Joshua N. Leonard a,d,e, Lonnie D. Shea a,b,c,d,e,*
aDepartment of Chemical and Biological Engineering, McCormick School of Engineering, Northwestern University, Evanston, IL, USA
bDepartment of Biomedical Engineering, McCormick School of Engineering, Northwestern University, Evanston, IL, USA
c Institute for BioNanotechnology in Medicine (IBNAM), Northwestern University, Chicago, IL, USA
dRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA
eChemistry of Life Processes Institute (CLP), Northwestern University, Evanston, IL, USA
a r t i c l e i n f o
Article history:
Received 19 October 2013
Accepted 13 November 2013








a b s t r a c t
Biomaterial scaffolds are central to many tissue engineering strategies as they create a space for tissue
growth and provide a support for cell adhesion and migration. However, biomaterial implantation results
in unavoidable injury resulting in an inflammatory response, which can impair integration with the host
and tissue regeneration. Toward the goal of reducing inflammation, we investigated the hypothesis that a
lentiviral gene therapy-based approach to localized and sustained IL-10 expression at a scaffold could
modulate the number, relative proportions, and cytokine production of infiltrating leukocyte pop-
ulations. Flow cytometry was used to quantify infiltration of six leukocyte populations for 21 days
following implantation of PLG scaffolds into intraperitoneal fat. Leukocytes with innate immune func-
tions (i.e., macrophages, dendritic cells, neutrophils) were most prevalent at early time points, while T
lymphocytes became prevalent by day 14. Reporter gene delivery indicated that transgene expression
persisted at the scaffold for up to 28 days and macrophages were the most common leukocyte trans-
duced, while transduced dendritic cells expressed the greatest levels of transgene. IL-10 delivery
decreased leukocyte infiltration by 50% relative to controls, increased macrophage IL-10 expression, and
decreased macrophage, dendritic cell, and CD4 T cell IFN-g expression. Thus, IL-10 gene delivery
significantly decreased inflammation following scaffold implant into the intraperitoneal fat, in part by
modulating cytokine expression of infiltrating leukocytes.
 2013 Elsevier Ltd. All rights reserved.
1. Introduction
Biomaterial scaffolds are central to many tissue-engineering
strategies and are employed to create an environment to promote
regeneration. Scaffolds create a space for tissue growth, support
host cell infiltration, and promote vascularization, all of which are
necessary for regeneration of lost or injured tissues. Scaffolds also
function as a platform for cell transplantation, such as islets for
diabetes therapies, retaining the transplanted cells within a defined
anatomical location, and as a support for cell infiltration that in-
tegrates transplanted cells with the host. Furthermore, scaffolds
may be modified with biological signals, such as extracellular ma-
trix (ECM) proteins to modulate cell adhesion and migration, or
inductive factors to stimulate or direct tissue growth. The biological
signals presented within the scaffold are ultimately aimed at
creating an environment for which endogenous or transplanted
progenitor cells can promote regeneration.
The innate immune response to implanted biomaterials plays a
crucial role in the post-injury microenvironment that can deter-
mine the extent of regeneration [1,2]. This immune response is
initiated by tissue resident leukocytes, including macrophages and
dendritic cells, which respond to the foreign material by secreting
chemokines that recruit peripheral leukocytes, initially neutrophils
and monocytes, to the implant site [3e5]. Infiltrating leukocytes
become activated at the implant, leading to release of pro-
inflammatory cytokines, such as IL-1b, TNF-a, and IFN-g [6,7],
which are well known to inhibit tissue regeneration or limit the
survival of transplanted tissue [8,9]. Conversely, up-regulation of
anti-inflammatory cytokines such as IL-10 is associated with reso-
lution of inflammation [10] and survival of transplanted cells [11].
Thus, modulating the inflammatory response has the potential to
enhance regenerative therapies.
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Localized delivery of immunomodulatory factors has emerged
as a strategy for controlling the immune response. Cells and tissues
have been engineered ex vivo to express immunomodulatory fac-
tors prior to transplantation, a strategy that has decreased rejection
of cell and organ transplants [12e14]. In addition, tissue-
engineering scaffolds have been designed to release proteins to
enhance angiogenesis or modulate inflammatory cell responses
[15,16]. However, a major hurdle for this approach is protein sta-
bility in the delivery system. More recently, gene delivery from
biomaterial scaffolds has been demonstrated as a versatile
approach to target infiltrating cells as bioreactors for the localized
production of factors [17]. Furthermore, gene delivery from bio-
materials has been shown to transduce leukocytes, providing the
opportunity to directly modulate the innate response [18e20]. For
example, plasmid-mediated production of IL-10 has been shown to
decrease the inflammatory response to stem cells in collagen
scaffolds thus increasing stem cell survival [11,21].
In this report, we investigated the hypothesis that a lentiviral
gene therapy-based approach to localized and sustained IL-10
expression could modulate the number, relative proportions, and
cytokine production of leukocyte populations infiltrating
poly(lactide-co-glycolide) (PLG) scaffolds. Using flow cytometry,
we quantified the infiltration of six major leukocyte populations
into PLG scaffolds implanted into the intraperitoneal (IP) fat.
Bioluminescence imaging was employed to characterize the level
and duration of transgene expression within PLG scaffolds
implanted with luciferase viruses, while flow cytometry was used
to identify the leukocyte populations expressing the transgene in
scaffolds delivering tdTomato viruses. Finally, flow cytometry was
employed to characterize leukocyte populations and their cytokine
expression within PLG scaffolds following viral IL-10 delivery.
Development of strategies to modulate the inflammatory response
has the potential to create a more permissive environment that can
enhance numerous applications within regenerative medicine.
2. Materials and methods
2.1. Animals
Animal studies were performed in accordance with the NIH Guide for the Care
and Use of Laboratory Animals, and protocols were approved by the IACUC at
Northwestern University. Male CD1 mice weighing 19e24 g were acquired from
Charles River and maintained in conventional housing.
2.2. Virus production
DNA encoding for murine IL-10 (Openbiosystems) or Luciferase (Promega) were
cloned into a self-inactivating lentiviral vector [22]. Lentivirus was produced in HEK-
293T cells grown in DMEM with 10% FBS at 37 C, and 5% CO2. The lentiviral pack-
aging vectors (pMDL-GagPol, pRSV-Rev, pIVS-VSV-G) were co-transfected with the
lentiviral vector into 293T cells using Lipofectamine 2000 (Life Technologies). After
48 h of transfection, the supernatant was collected and filtered (0.45 micron). Vi-
ruses were then concentrated using PEG-it (System Biosciences) and suspended
using sterile PBS. The virus titer was determined using a qPCR Lentivirus Titer Kit
(Applied Biological Materials). Typical titers ranged between 2  109 and
8  109 particles/mL.
2.3. Scaffold fabrication
Poly(lactide-co-glycolide) (PLG) microspheres were prepared as previously
described [23,24]. Briefly, PLG (75:25 mol ratio D,L-lactide to glycolide, 0.76 dL/g)
(Lakeshore Biomaterials) was dissolved in dichloromethane to make a 6% (w/w)
solution, which was then emulsified in 1% poly(vinyl alcohol) to create micro-
spheres. The microspheres were collected by centrifugation, washed with deionized
water, and lyophilized overnight. Microspheres were combined in a 1:30 ratio with
NaCl particles 250e425 mm diameter. The mixture was pressed in a steel die at
1500 pounds per square inch (psi) and gas-foamed after equilibration to 800 psi
under CO2 gas. Salt particles were removed by immersion in deionized water with
repeated washing. Scaffolds were sterilized in 70% ethanol and thenwashed twice in
sterile phosphate buffered saline (PBS; Life Technologies). 2  107 viral particles (in
PBS 2e10 mL) were added to the scaffold using a micropipette. Scaffolds were
immediately frozen on dry ice and stored in 80 C freezer until implantation.
2.4. In vitro cell studies
Scaffolds loaded with virus were seeded with murine RAW 264.7 macrophages
(ATCC) and incubated for 4 h at 37 C. Scaffolds were then transferred into wells
containing fresh media and imaged daily. Luciferase expression was measured by
adding d-luciferin (1 mM; Caliper) to the well 4 h before imaging on the IVIS
Spectrum (Caliper). The signal intensity was reported as an integrated light flux
(photons/s) as determined by Living Image Software (Caliper).
For cytokine production assays, scaffolds loaded with virus were seeded with
RAW 264.7 macrophages and cultured for 3 days prior to the addition of lipopoly-
saccharide (100 ng/ml; Sigma). Twenty-four hours after addition of lipopolysac-
charide, supernatants were collected. TNF-a and IL-10 production was measured by
ELISA (R&D systems).
2.5. Scaffold implantation
Mice received bilateral scaffold implants in the IP fat as previously described
[25]. Briefly, micewere anesthetized with an IP injection of ketamine (10mg/kg) and
xylazine (5 mg/kg), and the abdominal midline was shaved and prepped in a sterile
fashion. A midline lower abdominal incision was made, and the intraperitoneal (IP)
fat pads were identified. Scaffolds were wrapped in the right and left IP fat pads,
which were then inserted back into the IP cavity. Following scaffold implant, the
abdominal wall was closed with a running stitch and the skin was closed with
wound clips.
2.6. Flow cytometry
The following antibodies were purchased from Biolegend: anti-CD45 clone 30-
F11; anti-CD8a clone 53-6.7; anti-Gr1 clone RB6-8C5; anti-F4/80 clone BM8; anti-IL-
10 clone JES5-16E3; anti-TNF-a clone MP6-XT22; and anti-IFN-g clone XMG1.2. The
following antibodies were purchased from eBioscience: anti-CD11b clone M1/70;
anti-CD11c clone N418; and anti-IL-1b clone NJTEN3.
Following euthanization, scaffolds were harvested and immediately washed in
ice cold Hanks Balanced Salt Solution (HBSS; Life Technologies). Scaffolds were
minced and incubated in collagenase (Roche) at 37 C for 20 min. The solution was
then passed through a 70 mm filter, washed in HBSS, and suspended in antibodies
against extracellular antigens. After extracellular antibody incubation, cells were
washed to remove unbound antibody. In experiments where intracellular antigens
were detected, cells were then incubated with fixation buffer (eBioscience) and
permeabilization buffer (eBioscience) as per the manufacturer’s instructions. Cells
were then incubated with antibodies to intracellular antigens. After intracellular
antibody incubation, cells were washed to remove unbound antibody and analyzed
on an LSRFortessa flow cytometer (BD Biosciences; San Jose, CA, USA). The entire
sample from each scaffold was collected. Data was analyzed in FlowJo software
(Treestar). Isotype controls were used to set gates for immunophenotyping and cells
isolated from luciferase virus loaded scaffolds were used to set the gate for cells
positive for tdTomato expression.
The gating scheme for flow cytometry data is depicted in Sup. Fig. 1. Cellular
events were gated using forward scatter and side scatter (Sup. Fig. 1A). Leukocytes
were then identified by CD45 expression (Sup. Fig. 1B). Non-viable cells were then
excluded using LIVE/DEAD viability dye (Life Technologies) (Sup. Fig. 1C). CD4 pos-
itive cells (Q1) and CD8 positive cells (Q3) were then identified based on isotype
controls (Sup. Fig. 1F). These cells are referred to as CD4 T cells and CD8 T cells,
respectively. Cells negative for both CD4 and CD8 were then gated using Gr1 and F4/
80 (Sup. Fig. 1E). Cells positive for Gr1 (Q1) are referred to as neutrophils and F4/80
positive cells (Q2 and Q3) are referred to as macrophages. Cells negative for both Gr1
and F4/80 were then gated using CD11b and CD11c (Sup. Fig. 1D). Cells positive for
CD11c (Q2 and Q3) are referred to as dendritic cells. CD11b cells (Q1) are referred to
explicitly in the text.
2.7. In vivo bioluminescence imaging
Initial studies employed a luciferase virus to monitor transgene expression over
time. In vivo luciferase expression was monitored using an IVIS imaging system
(Caliper, Alameda, CA). Mice were anesthetized with isoflurane and then adminis-
tered an IP injection of d-luciferin (Caliper) at a dose 150 mg/kg. The animals were
then placed in the imaging chamber, and bioluminescence images were acquired
(every 2 min for a total of 20 min) until the peak light emission was confirmed.
Brightfield images and bioluminescence imageswere superimposed using the Living
Image software (Caliper). The signal intensity was reported as an integrated light
flux (photons/s) as determined by Living Image Software.
2.8. Statistics
Multiple groupswere compared using one-way ANOVAwith the Tukey post-hoc
test or by the Friedman test followed by Dunn’s Multiple Comparison Test. All other
comparisons were made with an unpaired t test. The specific test used is specified in
each figure legend. All analysis was carried out using GraphPad Prism.
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3. Results
3.1. Leukocyte infiltration into scaffolds
Initial studies focused on characterizing dynamic leukocyte
populations that infiltrate and reside within the microporous PLG
scaffolds. Flow cytometry revealed that leukocytes, identified by
CD45 expression, infiltrated the scaffold by day 3, and their
numbers remained at similar levels through day 21 (Fig. 1A).
However, the types of leukocytes associated with the scaffold
changed during this time frame (Fig. 1B). Cells positive for F4/80, a
macrophage marker, were the most numerous cell type at all time
points, constituting 40% of the total CD45 positive cells at day 3 but
decreasing to 25% by day 21. Similar trends were observed for cells
positive for Gr1 and CD11c, which are markers for neutrophils and
dendritic cells, respectively. In contrast, the proportion of CD4
positive cells significantly increased from 7% to 20% over this time
frame, while CD8 positive cells consistently made up less than 5% of
the cells in the scaffold. The remaining cells recovered from the
scaffold were CD11b positive, but not positive for any other markers
investigated. The presence of CD11b positive cells significantly
increased from day 3 to day 7 and then returned to day 3 levels.
3.2. Viral vector delivery from scaffolds
We next investigated gene delivery as a means to locally induce
protein production, which would be employed subsequently to
express IL-10. Scaffolds loaded with luciferase lentivirus were
implanted into the right IP fat pad. In vivo bioluminescence imaging
indicated that luciferase expressionwithin the IP fat region (Fig. 2A,
Fig. 2. Level and duration of transgene expression in vivo. (A) Representative bioluminescence images at days 3, 7, and 28 post implantation for scaffolds loaded with luciferase
lentivirus and implanted into the right IP fat pad. Color bar indicates radiance (p/sec/cm2/sr). (B) Total photon flux per second (p/s) from each region of interest (R1, red line; R2,
solid black line; R3, dotted black line), n ¼ 6 mice per group. *P < 0.05 compared to day 1. Statistics determined by the Friedman test followed by Dunn’s Multiple Comparison Test in
which fluxes through each region of interest at each time point were compared to day 1. (For interpretation of the references to color in this figure legend, the reader is referred to
the web version of this article.)
Fig. 1. Identification of leukocytes infiltrating PLG scaffolds. (A) Number of CD45 positive cells isolated from scaffolds at 3, 7, 14, and 21 days. (B) The percentage of CD45 positive
cells that also labeled positive for CD4, Gr1, F4/80, CD11c, CD11b, or CD8. Each mouse received bilateral scaffold implants, n ¼ 4 to 5 mice per group. *P < 0.05 compared to day 3.
#P < 0.05 compared to day 7. Statistics determined by One Way ANOVA with Tukey post-hoc test.
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red line) was at background levels at day 1, but maximal by day 3
and remained at similar levels through day 14 (Fig. 2B, R1). Lucif-
erase expression in the IP fat region was heterogeneous within the
group at days 21 and 28 and average levels were not significantly
different from day 1. Luciferase expression was also observed in
regions that correspond anatomically to the spleen (Fig. 2A, solid
black line) and the thymus or lungs (Fig. 2A, dotted black line),
which is consistent with previous reports and likely results from
migration of leukocytes that were transduced at the scaffold to
these tissues [19]. Luciferase expression at these sites was signifi-
cantly above day 1 at days 3 and 7 (Fig. 2B, R2 and R3).
3.3. Leukocyte transgene expression within scaffolds
We subsequently investigated which leukocytes were trans-
duced following lentivirus delivery. Transduced cells were
Fig. 3. Leukocyte transgene expression within PLG scaffolds at day 3. (A) Representative bivariate dot plots of F4/80 versus tdTomato fluorescence. Thresholds for tdTomato
fluorescence were set relative to cells isolated from scaffolds loaded with luciferase virus. (B) Percentage of F4/80, Gr1, CD11c, and CD4 cells that were also positive for tdTomato
fluorescence. *P < 0.05 compared to Gr1, CD11c, and CD4 positive cells. (C) The tdTomato median fluorescence intensity on F4/80, Gr1, CD11c, and CD4 positive cells. *P < 0.05 versus
CD11c positive cells. Each mouse received bilateral scaffolds implants, n ¼ 5 mice per group. Statistics determined by one-way ANOVA with Tukey post-hoc test.
Fig. 4. Macrophage phenotype on scaffolds in vitro. (A) Total photon flux per second (p/s) measured from RAW macrophages seeded on scaffolds loaded with different doses of
luciferase lentivirus particles (VP) and then treated with luciferin. n ¼ 4. *P < 0.0001 versus 1  107 VP and background. Statistics determined by two-way ANOVA with Bonferroni
post-hoc test. (B) TNF-a and IL-10 production by RAWmacrophages seeded on scaffolds loaded with 2  107 VP encoding for IL-10 (vIL-10) or luciferase (vCtrl) and then treated with
LPS (þLPS). Empty scaffold (NT) and no LPS (-LPS) controls were included. Cytokine production measured by ELISA. n ¼ 4e5. *P < 0.001 versus corresponding vCtrl. **P < 0.001
versus vIL-10 (-LPS). Statistics determined by one-way ANOVA with Tukey post-hoc test.
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determined by detection of tdTomato expression by flow cytom-
etry, with the identity of these cells determined by antibody
staining of surface markers (Fig. 3A). Three days after scaffold
implant F4/80, Gr1, CD11c, and CD4 positive cells were positive for
tdTomato expression. Approximately 15 percent of all F4/80 posi-
tive cells were positive for tdTomato expression, which was
significantly greater than for Gr1, CD11c, and CD4 positive cells that
ranged from 3% to 6% (Fig. 3B). In addition, approximately 13% of
tdTomato positive cells were negative for leukocyte markers indi-
cating other cell types such as adipocytes, fibroblasts, or endothelial
cells were also transduced (data not shown). Interestingly, F4/80
and Gr1 positive cells had the lowest mean fluorescence intensity
for tdTomato, suggesting relatively low levels of protein production
per cell or high levels of protein degradation (Fig. 3C). In contrast,
CD11c positive cells had the greatest fluorescence intensity for
tdTomato per cell.
3.4. Macrophage phenotype on scaffolds in vitro
Gene delivery from PLG scaffolds was subsequently investigated
in vitro to determine if macrophage phenotype could bemodulated,
as measured by a reduction in TNF-a production and an increase in
IL-10 production. A lentivirus dose of 2  107 viral particles (VP)
was determined to be necessary for achieving transgene expression
levels that were significantly above background (Fig. 4A). Gene
expression by the cells was observed to increase through day 3, and
subsequently decline through day 7. IL-10 lentivirus delivery from
the scaffold, followed by LPS-induction of cytokine production at
day 3 (peak transgene expression), resulted in a significant
decrease in TNF-a production relative to no treatment and virus
control (Fig 4B). Furthermore, a significant increase in IL-10 pro-
duction was observed relative to control virus, no treatment, and
LPS negative controls. These data indicate the scaffold based viral
delivery of IL-10 is capable of modulating macrophage cytokine
expression in response to an acute inflammatory stimulus.
3.5. Leukocyte infiltration into IL-10 virus releasing scaffolds
We hypothesized that localized IL-10 expression from the scaf-
fold would modulate the infiltration of leukocytes and their
phenotype. At 3 days post implantation of IL-10 lentivirus loaded
scaffolds, the number of leukocytes in the scaffold was not signif-
icantly different between the scaffolds loaded with an IL-10 or
luciferase control virus. However, seven days post implantation,
leukocyte infiltration significantly decreased relative to control
(Fig. 5A). At both time points, the scaffolds loaded with luciferase
virus had similar numbers of leukocytes compared to blank scaf-
folds (Fig. 1A), indicating that vector delivery did not significantly
affect leukocyte infiltration. Both the number of F4/80 and Gr1
positive cells was significantly decreased on day 7 within scaffolds
loaded with IL-10 virus compared to scaffolds loaded with lucif-
erase virus (Fig. 5B). However, at day 7, the relative percentages of
leukocyte populations were not significantly changed for the cell
types investigated, though the greatest trend was a decrease in the
percentage of F4/80 positive cells (Fig. 5C).
3.6. Cytokine production within IL-10 virus releasing scaffolds
A hallmark of the host response is inflammatory cytokine
expression such as IL-1b, IFN-g, and TNF-a, while resolution of
inflammation is characterized by IL-10 expression. Flow cytometry
indicated that F4/80 positive cells isolated from IL-10 releasing
scaffolds had a greater mean fluorescence intensity following IL-10
antibody staining relative to F4/80 positive cells isolated from
luciferase releasing scaffolds, indicating elevated IL-10 expression
(Fig. 6A). Furthermore, in IL-10 releasing scaffolds, F4/80 positive
cells expressed significantly more IL-10 than did CD4 and CD11c
positive cells. No significant difference in IL-10 expression in CD4
and CD11c positive cells was detected between the two groups. We
next investigated expression of the pro-inflammatory cytokines IL-
1b, IFN-g, and TNF-a (Fig. 6BeD). In scaffolds delivering IL-10, we
observed that CD4, F4/80, and CD11c positive cells expressed
significantly less IFN-g compared to cells isolated from control
scaffolds. No significant differences in intracellular TNF-a and IL-1b
expression were observed between the two groups; however, TNF-
a exhibited a decreasing trend for all cell types.
4. Discussion
The innate immune response to the implanted biomaterials
contributes to the post-injury microenvironment that influences
the extent of regeneration [1,2]. Excessive inflammation can
impede the implant’s integration with the host and tissue regen-
eration, and can adversely affect the survival and function of cells
delivered by the scaffold [1]. We characterized the host response to
porous PLG scaffolds implanted in the IP fat, an anatomical site that
Fig. 5. Leukocyte infiltration into IL-10 virus releasing scaffolds. (A) Number of CD45
positive cells isolated from scaffolds loaded with IL-10 or luciferase virus at day 3 and
day 7 post implantation. *P < 0.05 versus day 7 luciferase. (B) Number of CD4, Gr1, F4/
80, CD11c, CD11b, or CD8 cells isolated from scaffolds loaded with IL-10 or luciferase
virus at day 7. (C) The percentage of CD45 positive cells that were CD4, Gr1, F4/80,
CD11c, CD11b, or CD8 positive at day 7. *P < 0.05 versus luciferase for each cell type.
Each mouse received bilateral scaffolds implants. 5 mice per group. Statistics deter-
mined by t-test.
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has been employed for cell transplantation, such as islets for dia-
betes therapies [25e29]. Multicolor flow cytometry was used to
characterize the kinetics of leukocyte infiltration of six major
leukocyte populations within the scaffold at 4 time points post-
implant. Leukocytes were present within the scaffold as early as
day 3 and remained at similar numbers through day 21. Macro-
phages were the most prevalent leukocyte found in the scaffold at
all time points, consistent with previous studies [11,18,20,21,24,30].
The studies herein also quantified the frequency of other leukocyte
populations, and detected members of the adaptive immune sys-
tem such as T cells. Thus strategies to modulate inflammation, and
ultimately immunity, within biomaterial implants will need to in-
fluence cellular processes (e.g., leukocyte infiltration) at or near the
time of implantation.
IL-10 delivery decreased leukocyte numbers within the scaffold,
an effect observed at day 7 but not day 3. The inability to influence
leukocyte numbers at day 3 likely results from the gene expression
profile of the IL-10, which in vivo bioluminescence imaging sug-
gests was low prior to day 3 and peaks between day 3 and 14. The
decreased leukocyte numbers within the scaffold was primarily
due to a decrease in the number of macrophages. The ability to
decrease macrophage infiltration is significant in the context of
tissue engineering as their adhesion to biomaterial scaffolds can
result in macrophage activation [31,32]. Macrophage activation
involves the release of cytokines, which recruit and activate addi-
tional leukocytes leading to impairment of wound healing [8],
clinical failure of medical devices [33], and the rejection of non-
autologous tissue. The significance of reduced macrophage infil-
tration is exemplified with studies of islet transplantation. Macro-
phage infiltration into islet grafts results in early rejection, while
systemic macrophage depletion significantly improves islet graft
survival [34e36]. A consequence of systemicmacrophage depletion
would be an impaired host defense and wound healing [37,38].
Thus, a localized strategy to exclude macrophages from the
biomaterial or transplant site could create a microenvironment
more favorable to survival of transplanted cells while minimizing
the risk of systemic consequences.
A cellular level analysis, enabled by flow cytometry, indicated
that following viral IL-10 delivery from scaffolds, macrophages up-
regulated IL-10, while macrophages, dendritic cells, and CD4 T cells
down-regulated the production of the inflammatory cytokine IFN-
g. Many studies have characterized bulk cytokine expressionwithin
and around implanted biomaterial scaffolds [6,7,11]. Herein, we
identify the cytokines levels within specific cell types in situ.
Macrophages were the highest producers of IL-10 following IL-10
gene delivery, which likely contributed to the reduction in leuko-
cyte infiltration into the scaffold. Decreased IFN-g levels within
macrophages, dendritic cells, and T cells were observed within
scaffolds inducing IL-10 expression. IFN-g typically converts resting
macrophages into cells with increased capacity for antigen pre-
sentation, pro-inflammatory cytokine synthesis, and phagocytosis
[39], thus playing a key role in allogeneic tissue rejection [40]. The
ability to modulate both IL-10 and IFN-g production within the
scaffold would be expected to contribute to a more favorable
environment for regeneration or survival and function of trans-
planted cells.
Leukocytes were transduced directly with delivery of the gene
therapy vector, with macrophages being the most transduced
leukocyte and dendritic cells exhibiting the greatest intracellular
transgene-encoded protein production. Previous studies have re-
ported that both macrophages and dendritic cells exhibit transgene
expression within plasmid [18,24,30] and viral-based [19] gene
releasing scaffolds. Histological analysis identified these cells
within the scaffold and preferentially located near the polymer
surface, yet histology was unable to identify transgene expression
levels. Despite producing less tdTomato than dendritic cells,
Fig. 6. Cytokine production within IL-10 virus releasing scaffolds. (A) IL-10, (B) IFN-g, (C) IL-1b, and (D) TNF-a expression as measured by median fluorescence intensity (MFI) on
CD4, F4/80, and CD11c positive cells isolated from scaffolds loaded with either luciferase or IL-10 encoding virus. *P < 0.05 for F4/80 positive cell IL-10 expression relative to
luciferase scaffolds by t-test. P̂ < 0.05 versus bars as indicated with line by one-way ANOVA with Tukey post-hoc test. **P < 0.05 versus luciferase for each cell type by t-test. Each
mouse received bilateral scaffolds implants, n ¼ 5 mice per group.
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macrophages were the greatest producer of IL-10 following de-
livery of the lentivirus encoding IL-10. This discrepancy in protein
production could be due to positive feedback loops present in
macrophages, in which IL-10 signaling induces increased IL-10
production [41]. Viral delivery is also known to transduce non-
leukocytes present in and around the scaffold [19,20,42] and our
results here indicate that a subset of tdTomato positive cells were
not leukocytes. Thus adipocytes, fibroblasts, or endothelial cells
present around the scaffolds likely also contributed to IL-10
transgene expression responsible for the leukocyte numbers and
cytokine expression observed within the scaffold.
5. Conclusions
Following scaffold implantation into the intraperitoneal fat,
leukocyte infiltration reached maximal levels by day 3-post
implant and remained at similar levels through day 21, with mac-
rophages being the most prevalent cell type within the scaffold at
all time points. Delivery of an IL-10 encoding vector significantly
decreased leukocyte infiltration, increased macrophage IL-10
expression, and decreased macrophage, dendritic cell, and CD4 T
cell IFN-g expression. Macrophages were the most commonly
transduced leukocyte in this system, while transduced dendritic
cells expressed the highest level of the transgene, indicating that
modulation of leukocyte infiltration and IFN-g expression likely
occurred through both autocrine and paracrine signaling mecha-
nisms. This study characterized the role that leukocyte populations
play in modulating the local immune environment following IL-10
expression at tissue engineering scaffolds, which has implications
for the design of combinatorial delivery devices for local
immunomodulation.
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